Congratulations to Ann Arbor-based Swift Biosciences! At the 18th International Molecular Medicine Tri-Conference, the company presented quantitative polymerase chain reaction (qPCR) assays that can detect mutations in two cancer genes.
In a company announcement, David Olsen, CEO, said, “We expect to begin commercializing the myT Primer qPCR assays later this year. At this time we are looking for industrial partners who would like to incorporate the myT Primers advantages into their kits or processes.”
Swift Biosciences is an innovative developer molecular biology protocols and reagents for research and diagnostic research applications. The Company’s novel platform technologies are being developed for qPCR and Next Generation Sequencing markets. Swift Biosciences’ products are designed to produce better and faster results, at lower cost and be compatible with customers’ existing systems.
